Pancreatic Cancer Research

ResearcherWayne State UniversityNo recent work listed

Fazlul H. Sarkar

Verified by OpenAlex author ID and NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5109278193, A5109719650, A5159689277; NIH RePORTER profile ID 7020611. Sources: ClinicalTrials.gov.

Their work

Papers
41 (first author 2, last author 24)
Trials
2 (principal investigator on 2)
Grants
3
Labs led
1
Collaborators
42
Papers, trials and grants by year

2005: 2 trials · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 12 papers · 2012: 11 papers, 1 grant · 2013: 7 papers, 1 grant · 2014: 4 papers · 2015: 4 papers, 1 grant · 2016: 1 paper · 2017: none · 2018: 2 papers

Papers 41

  1. Retraction notice to "Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells" [Cancer Lett. 31… Last author DOI 10.1016/j.canlet.2017.11.030↗
  2. Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells". Last author DOI 10.1016/j.canlet.2018.03.020↗
  3. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer. First author DOI 10.7150/ijbs.15017↗
  4. Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer. Co-author DOI 10.1016/j.colsurfb.2015.05.007↗
  5. Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells. Co-author DOI 10.1016/j.colsurfb.2015.09.043↗
  6. Hyaluronic Acid Engineered Nanomicelles Loaded with 3,4-Difluorobenzylidene Curcumin for Targeted Killing of CD44+ Stem-Like Pancreatic Cancer Cells. Co-author DOI 10.1021/acs.biomac.5b00941↗
  7. The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome. Last author DOI 10.1097/mpa.0000000000000257↗
  8. Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. Last author DOI 10.1016/j.canlet.2014.05.013↗
  9. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. Last author DOI 10.1074/jbc.m113.532887↗
  10. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Last author DOI 10.1089/scd.2013.0551↗
  11. Systems biology approaches to pancreatic cancer detection, prevention and treatment. Co-author DOI 10.2174/138161282001140113124643↗
  12. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. Last author DOI 10.1002/jcp.24162↗
  13. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures. Co-author DOI 10.1002/mnfr.201200297↗
  14. Synthesis, characterization and anti-tumor activity of novel thymoquinone analogs against pancreatic cancer. Co-author DOI 10.1016/j.bmcl.2013.03.003↗
  15. Pancreatic cancer stem cells: emerging target for designing novel therapy. Last author DOI 10.1016/j.canlet.2012.03.018↗
  16. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Co-author DOI 10.1053/j.gastro.2012.10.036↗
  17. CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth. Co-author DOI 10.1593/tlo.13133↗
  18. Genistein down-regulates miR-223 expression in pancreatic cancer cells. Co-author DOI 10.2174/13894501113149990187↗
  19. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. Last author DOI 10.1002/jcp.24036↗
  20. Inclusion complex of novel curcumin analogue CDF and β-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Last author DOI 10.1007/s11095-012-0700-1↗
  21. Targeting pancreatic cancer stem cells for cancer therapy. Co-author DOI 10.1016/j.bbcan.2012.06.002↗
  22. RETRACTED: Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Last author DOI 10.1016/j.canlet.2012.01.013↗
  23. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2012.383↗
  24. Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Last author DOI 10.1093/carcin/bgs189↗
  25. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Last author DOI 10.1158/1940-6207.capr-11-0299↗
  26. The tyrosine kinase c-Src directly mediates growth factor-induced Notch-1 and Furin interaction and Notch-1 activation in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0033414↗
  27. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. Last author DOI 10.1371/journal.pone.0050165↗
  28. Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Co-author DOI 10.2174/138945012804545597↗
  29. Emerging Role of MicroRNA in Pancreatic Cancer. First author DOI 10.4172/2165-7092.1000e114↗
  30. Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Last author DOI 10.1002/ijc.25658↗
  31. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. Last author DOI 10.1002/jcb.23150↗
  32. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Co-author DOI 10.1007/s10637-010-9386-6↗
  33. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Last author DOI 10.1016/j.bbcan.2010.11.003↗
  34. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Last author DOI 10.1016/j.canlet.2011.03.012↗
  35. Pancreatic cancer: understanding and overcoming chemoresistance. Last author DOI 10.1038/nrgastro.2010.188↗
  36. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. Last author DOI 10.1371/journal.pone.0017850↗
  37. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. Last author DOI 10.1371/journal.pone.0020537↗
  38. Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Last author DOI 10.2217/epi.11.97↗
  39. Garcinol-induced apoptosis in prostate and pancreatic cancer cells is mediated by NF- kappaB signaling. Co-author DOI 10.2741/e349↗
  40. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Last author PMID 21508353↗
  41. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Last author PMID 21904657↗

Trials 2

  1. Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Principal investigator NCT00376948↗
  2. Identification of Biomarkers for Early Detection of Pancreatic Cancer Principal investigator NCT00897494↗

Grants 3

  1. Prevention of Tumor Progression by a Novel Approach R01CA154321↗
  2. FoxM1: A molecular target in pancreatic cancer R01CA132794↗
  3. RO1: A novel and targeted approach to inhibit invasion and angiogenesis R01CA131151↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sanjeev Banerjee · 24 shared papers, 2011–2018 · strength 0.90
  2. Bin Bao · 20 shared papers, 2011–2018 · strength 0.75
  3. Shadan S. Ali · 17 shared papers, 2011–2018 · strength 0.65
  4. Asfar Sohail Azmi · 16 shared papers, 2011–2018 · strength 0.57
  5. Yiwei Li · 12 shared papers, 2011–2018 · strength 0.52
  6. Subhash Padhyé · 10 shared papers, 2011–2018 · strength 0.46
  7. Philip A. Philip · 9 shared papers, 2011–2018 · strength 0.38
  8. Amro Aboukameel · 9 shared papers, 2011–2018 · strength 0.38
  9. Lucio Miele · 8 shared papers, 2011–2018 · strength 0.28
  10. Zhiwei Peter Wang · 7 shared papers, 2011–2018 · strength 0.26
  11. Prashant Kesharwani · 3 shared papers, 2015 · strength 0.19
  12. Arun K. Iyer · 3 shared papers, 2015 · strength 0.19
  13. Jun Xia · 4 shared papers, 2012–2013 · strength 0.16
  14. Ramzi M. Mohammad · 4 shared papers, 2011–2014 · strength 0.14
  15. Zhiwei Wang · 4 shared papers, 2011–2013 · strength 0.12
  16. Murray Korc · 3 shared papers, 2011–2013 · strength 0.09
  17. Yiwei Li · 1 shared paper, 2015 · strength 0.08
  18. Vay Liang W. Go · 1 shared paper, 2015 · strength 0.08
  19. P. A. Philip · 2 shared papers, 2012 · strength 0.08
  20. S. Ali · 2 shared papers, 2012 · strength 0.08
  21. Jia Ma · 2 shared papers, 2012–2013 · strength 0.06
  22. Osama M. Alian · 1 shared paper, 2014 · strength 0.06
  23. Mansi A. Parasramka · 1 shared paper, 2013 · strength 0.04
  24. SmitiV. Gupta · 1 shared paper, 2013 · strength 0.04
  25. Omar Soubani · 1 shared paper, 2012 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.